Submit Your Article CMED MEACR meeting
An official publication of the Middle-Eastern Association for Cancer Research
Clinical Cancer Investigation Journal
ARTICLE
Year: 2021   |   Volume: 10   |   Issue: 6   |   Page: 294-299     View issue

Sarcopenia is a predictive marker for response to erlotinib in patients with lung adenocancer


Havva Cinkir, Tulay Kus, Gokmen Aktas, Umut Elboga
Abstract

Background: Adenocancer pathologic subtype, smoking history, and women gender have been known to predict the parameters such as the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer (NSCLC); however, we need new predictive markers as well as driver mutations for better treatment options. The aim of this study is to investigate the predictive role of sarcopenia in lung adenocancer patients treated with erlotinib. Materials and Methods: This study was designed as retrospectively. Skeletal muscle index (SMI) was measured with a single cross-sectional area of the muscle at the third lumber vertebra (L3, cm2)/(height × height)(m2). Sarcopenia was defined by median cutoff values of SMI of women (<28.2 cm2/m2) and men (<32.7 cm2/m2). The predictive role of sarcopenia and other parameters was assessed by the cox-regression model. Results: The median age was 56 years (range, 36–84). Median progression-free survival (PFS) was 38 (95% confidence interval [CI]: 21.3–54.6) weeks in the sarcopenic group and 49 (95% CI: 0–101.4) weeks in the nonsarcopenic group (P = 0.053). In multivariate analysis, the presence of sarcopenia and number of metastatis were the independent predictive factors for PFS. Disease control rate and overall survival were not significantly different between sarcopenic and nonsarcopenic groups. Conclusion: We found that the presence of sarcopenia and number of metastasis were a predictive marker in NSCLC patients treated with erlotinib. It is important to recognize sarcopenia early and manage patients accordingly.

Cite this article
Vancouver
Cinkir H, Kus T, Aktas G, Elboga U. Sarcopenia is a predictive marker for response to erlotinib in patients with lung adenocancer. Clin Cancer Investig J. 2021;10(6):294-9. https://doi.org/10.4103/ccij.ccij_185_20
APA
Cinkir, H., Kus, T., Aktas, G., & Elboga, U. (2021). Sarcopenia is a predictive marker for response to erlotinib in patients with lung adenocancer. Clinical Cancer Investigation Journal, 10(6),294-299. https://doi.org/10.4103/ccij.ccij_185_20

Sitemap | What's New Feedback | Copyright and Disclaimer | Privacy Notice
© Clinical Cancer Investigation Journal | Published by Wolters Kluwer - Medknow
Online since 01 December, 2011
Editorial and Ethics Policies
Creative Commons  Open Access Journal No author-side fee  View mobile site 
ISSN: Print -2278-1668, Online - 2278-0513